Third View Private Wealth LLC Takes Position in Haleon PLC Sponsored ADR $HLN

Third View Private Wealth LLC purchased a new stake in Haleon PLC Sponsored ADR (NYSE:HLN) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 342,380 shares of the company’s stock, valued at approximately $3,461,000.

A number of other institutional investors and hedge funds have also made changes to their positions in HLN. Brighton Jones LLC purchased a new position in shares of Haleon in the 4th quarter valued at $187,000. AQR Capital Management LLC increased its holdings in shares of Haleon by 22.5% in the 1st quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock valued at $991,000 after acquiring an additional 17,720 shares during the period. Focus Partners Wealth increased its holdings in shares of Haleon by 7.6% in the 1st quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock valued at $752,000 after acquiring an additional 5,178 shares during the period. Geneos Wealth Management Inc. increased its holdings in shares of Haleon by 33.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after acquiring an additional 1,203 shares during the period. Finally, CW Advisors LLC increased its holdings in shares of Haleon by 11.6% in the 2nd quarter. CW Advisors LLC now owns 25,075 shares of the company’s stock valued at $260,000 after acquiring an additional 2,601 shares during the period. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Stock Down 0.2%

Shares of HLN stock opened at $9.83 on Tuesday. Haleon PLC Sponsored ADR has a 1-year low of $8.71 and a 1-year high of $11.42. The stock’s fifty day moving average price is $10.44 and its 200 day moving average price is $9.93. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The company has a market cap of $43.81 billion, a price-to-earnings ratio of 25.19 and a beta of 0.26.

Haleon (NYSE:HLN) last announced its earnings results on Saturday, February 14th. The company reported $6.32 earnings per share for the quarter. The business had revenue of $3.65 billion for the quarter. On average, research analysts expect that Haleon PLC Sponsored ADR will post 0.43 earnings per share for the current fiscal year.

Haleon Announces Dividend

The firm also recently announced a dividend, which will be paid on Thursday, May 14th. Investors of record on Friday, April 10th will be paid a dividend of $0.1307 per share. This represents a yield of 266.0%. The ex-dividend date is Friday, April 10th. Haleon’s payout ratio is 64.10%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Wall Street Zen upgraded Haleon from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Deutsche Bank Aktiengesellschaft downgraded Haleon from a “hold” rating to a “sell” rating in a report on Monday, January 12th. HSBC upgraded Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Argus upgraded Haleon to a “strong-buy” rating in a report on Tuesday, March 17th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a report on Monday, December 15th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Haleon has an average rating of “Moderate Buy” and a consensus price target of $12.33.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.